^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    DRD2 antagonist

    Related drugs:
    14h
    Selected Disorders and Sleep Bruxism (clinicaltrials.gov)
    P=N/A, N=100, Enrolling by invitation, Wroclaw Medical University | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date
    18h
    VCFS: The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (clinicaltrials.gov)
    P4, N=400, Recruiting, The Chaim Sheba Medical Center | Trial completion date: Dec 2022 --> Aug 2024 | Trial primary completion date: Dec 2022 --> Aug 2024
    Trial completion date • Trial primary completion date
    1d
    Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia (clinicaltrials.gov)
    P4, N=26, Completed, Weill Medical College of Cornell University | N=47 --> 26
    Enrollment change
    1d
    Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer (clinicaltrials.gov)
    P3, N=0, Withdrawn, Mayo Clinic | Trial completion date: Jun 2024 --> Dec 2024
    Trial completion date • Metastases
    |
    olanzapine
    5d
    PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects (clinicaltrials.gov)
    P1, N=12, Recruiting, Intra-Cellular Therapies, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    6d
    Adverse hematological profiles associated with chlorpromazine antipsychotic treatment in male rats: Preventive and reversal mechanisms of taurine and coenzyme-Q10. (PubMed, Toxicol Rep)
    Taurine and COQ-10 alone notably improved the antioxidant/anti-inflammatory status relative to controls. Among other mechanisms, taurine and COQ-10 abated CPZ-induced hematological deficiencies, via decreased serum levels of oxidative stress, and pro-inflammatory cytokines release, with increased antioxidants and anti-inflammation function.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
    |
    IL10 elevation
    6d
    Haloperidol for Pain Control in Patients With Acute Musculoskeletal Back Pain in the Emergency Department (clinicaltrials.gov)
    P4, N=75, Not yet recruiting, Western Michigan University School of Medicine
    New P4 trial
    6d
    Restoration of Hypoglycemia Awareness With Metoclopramide (clinicaltrials.gov)
    P2, N=36, Recruiting, Simon Fisher | Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Mar 2024 --> Mar 2026
    Trial completion date • Trial primary completion date
    6d
    Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced and Incurable Solid Tumors (clinicaltrials.gov)
    P2, N=66, Recruiting, OHSU Knight Cancer Institute | Suspended --> Recruiting | N=44 --> 66 | Trial completion date: Nov 2024 --> Dec 2025 | Trial primary completion date: Nov 2024 --> Jun 2025
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    olanzapine
    11d
    Metabolic and inflammatory parameters in relation to baseline characterization and treatment outcome in patients with prolactinoma: insights from a retrospective cohort study at a single tertiary center. (PubMed, Front Endocrinol (Lausanne))
    Treatment outcomes were evaluated based on prolactin normalization, tumor shrinkage, and cabergoline dosage...However, inflammatory markers were not significantly correlated with patient stratification or outcome prediction. These findings highlight the necessity for standardized follow-up protocols and further research into the metabolic pathogenesis in PRL patients.
    Retrospective data • Journal
    |
    PRL (Prolactin)
    13d
    Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients (clinicaltrials.gov)
    P2/3, N=410, Recruiting, Acacia Pharma Ltd | Not yet recruiting --> Recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
    Enrollment open • Trial completion date • Trial primary completion date
    |
    dexamethasone injection
    14d
    Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder (clinicaltrials.gov)
    P3, N=485, Completed, Intra-Cellular Therapies, Inc. | Active, not recruiting --> Completed
    Trial completion
    16d
    SOLARIS: A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia (clinicaltrials.gov)
    P3, N=675, Active, not recruiting, Teva Branded Pharmaceutical Products R&D, Inc. | Trial completion date: Oct 2025 --> Jan 2025 | Trial primary completion date: Oct 2024 --> Mar 2024
    Trial completion date • Trial primary completion date
    |
    olanzapine
    19d
    The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine (clinicaltrials.gov)
    P4, N=13, Terminated, Sumitomo Pharma (Suzhou) Co., Ltd. | N=162 --> 13 | Active, not recruiting --> Terminated; Company's business decision
    Enrollment change • Trial termination
    |
    olanzapine
    19d
    Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients (clinicaltrials.gov)
    P4, N=102, Terminated, Sumitomo Pharma (Suzhou) Co., Ltd. | N=248 --> 102 | Recruiting --> Terminated; Company's business decision
    Enrollment change • Trial termination
    |
    BDNF (Brain Derived Neurotrophic Factor)
    20d
    The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients (clinicaltrials.gov)
    P=N/A, N=3192, Completed, Sumitomo Pharma (Suzhou) Co., Ltd. | Enrolling by invitation --> Completed | Trial completion date: Jun 2024 --> Jun 2023
    Trial completion • Trial completion date
    20d
    Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients (clinicaltrials.gov)
    P3, N=384, Recruiting, Intra-Cellular Therapies, Inc.
    New P3 trial
    20d
    DSPCLAT-003: The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia (clinicaltrials.gov)
    P4, N=200, Completed, Sumitomo Pharma (Suzhou) Co., Ltd. | Enrolling by invitation --> Completed
    Trial completion
    22d
    Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder (clinicaltrials.gov)
    P3, N=417, Completed, Vanda Pharmaceuticals | Active, not recruiting --> Completed
    Trial completion
    26d
    HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial (clinicaltrials.gov)
    P3, N=72, Recruiting, Tan Tock Seng Hospital | Trial completion date: Apr 2023 --> Dec 2024 | Trial primary completion date: Apr 2023 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    olanzapine
    28d
    Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia (clinicaltrials.gov)
    P3, N=564, Recruiting, Abbott | Not yet recruiting --> Recruiting
    Enrollment open • Head-to-Head
    28d
    Treatment of hyperprolactinemia in women: A Position Statement from the Brazilian Federation of Gynecology and Obstetrics Associations (Febrasgo) and the Brazilian Society of Endocrinology and Metabolism (SBEM). (PubMed, Arch Endocrinol Metab)
    The use of some drugs, such as antidepressants and antipsychotics, is a frequent cause of hyperprolactinemia, and managing this occurrence involves unique considerations. This position statement by the Brazilian Federation of Gynecology and Obstetrics Associations (Febrasgo) and Brazilian Society of Endocrinology and Metabolism (SBEM) addresses the recommendations for measurement of serum prolactin levels and the investigations of symptomatic and asymptomatic hyperprolactinemia and drug-induced hyperprolactinemia in women.
    Journal
    |
    PRL (Prolactin)
    29d
    Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia (clinicaltrials.gov)
    P4, N=60, Recruiting, All India Institute of Medical Sciences, Bhubaneswar | Not yet recruiting --> Recruiting
    Enrollment open
    29d
    NCI-2018-02438: Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care (clinicaltrials.gov)
    P2/3, N=110, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=206 --> 110 | Trial primary completion date: May 2024 --> Aug 2023
    Enrollment closed • Enrollment change • Trial primary completion date • Metastases
    30d
    Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder. (clinicaltrials.gov)
    P1, N=95, Recruiting, Teva Branded Pharmaceutical Products R&D, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    olanzapine
    1m
    Exploring neuroadaptive cellular pathways in chronic morphine exposure: An in-vitro analysis of cabergoline and Mdivi-1 co-treatment effects on the autophagy-apoptosis axis. (PubMed, J Cell Biochem)
    The impact of Methadone, Cabergoline, and a combination of Cabergoline and Mdivi-1 on the cellular and molecular responses associated with Morphine-induced changes was studied in human Neuroblastoma (SK-N-MC) and Glioblastoma (U87-MG) cell lines that were exposed to prolong Morphine treatment. This highlights the potential for new treatments in the DRD2 pathway and underscores the importance of investigating the interplay between autophagy and apoptosis to advance research in managing cancer-related pain. The study necessitates an in-depth investigation into the relationship between autophagy and apoptosis, with a specific emphasis on protein interactions and the dynamics of cell signaling.
    Preclinical • Journal
    |
    PCNA (Proliferating cell nuclear antigen) • DRD2 (Dopamine Receptor D2)
    1m
    Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma (clinicaltrials.gov)
    P1, N=0, Withdrawn, Koen van Besien | N=20 --> 0 | Trial completion date: Sep 2023 --> Mar 2024 | Recruiting --> Withdrawn | Trial primary completion date: Jun 2023 --> Dec 2023
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    captisol-enabled melphalan
    1m
    Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial (clinicaltrials.gov)
    P3, N=87, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    olanzapine
    1m
    An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia (clinicaltrials.gov)
    P1, N=116, Recruiting, Teva Branded Pharmaceutical Products R&D, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    olanzapine
    1m
    Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI) (clinicaltrials.gov)
    P3, N=146, Not yet recruiting, Foundation for Advancing Veterans' Health Research
    New P3 trial
    1m
    Comparative Study Between Calcium Gluconate With Diosmin, Cabergoline and Cabergoline With Diosmin (clinicaltrials.gov)
    P=N/A, N=180, Completed, Minia University
    New trial
    1m
    Domperidone inhibits cell proliferation via targeting MEK and CDK4 in esophageal squamous cell carcinoma. (PubMed, Cancer Cell Int)
    Collectively, these findings suggest that domperidone serves as an effective "multi-target" inhibitor of MEK1/2 and CDK4, offering potential benefits for the chemoprevention of ESCC.
    Journal
    |
    CDK4 (Cyclin-dependent kinase 4) • SMAD3 (SMAD Family Member 3)
    1m
    Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia (clinicaltrials.gov)
    P1, N=36, Recruiting, Teva Branded Pharmaceutical Products R&D, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    olanzapine
    2ms
    A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis (clinicaltrials.gov)
    P2, N=0, Withdrawn, Vanda Pharmaceuticals | N=24 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    2ms
    Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia (clinicaltrials.gov)
    P4, N=50, Recruiting, University of Massachusetts, Worcester | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    Effect of Metoclopramide Versus Erythromycin on on Gastric Residual Volume (clinicaltrials.gov)
    P4, N=50, Completed, Cairo University | Enrolling by invitation --> Completed | Phase classification: P1 --> P4 | Trial completion date: Feb 2022 --> Feb 2024 | Trial primary completion date: Jan 2022 --> Feb 2024
    Trial completion • Phase classification • Trial completion date • Trial primary completion date
    2ms
    Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder. (clinicaltrials.gov)
    P1, N=95, Not yet recruiting, Teva Branded Pharmaceutical Products R&D, Inc.
    New P1 trial
    |
    olanzapine
    2ms
    Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder (clinicaltrials.gov)
    P3, N=480, Active, not recruiting, Intra-Cellular Therapies, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    2ms
    Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder (clinicaltrials.gov)
    P1, N=89, Completed, Luye Pharma Group Ltd. | Recruiting --> Completed
    Trial completion
    2ms
    An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia (clinicaltrials.gov)
    P1, N=116, Not yet recruiting, Teva Branded Pharmaceutical Products R&D, Inc.
    New P1 trial
    |
    olanzapine
    2ms
    The cytotoxic effects of prazosin, chlorpromazine, and haloperidol on hepatocellular carcinoma and immortalized non-tumor liver cells. (PubMed, Med Oncol)
    Based on our findings, a mechanism of cell death was not able to be established due to lack of cleaved caspase-3 expression. Capable of bypassing many aspects of the lengthy, costly, and difficult cancer drug approval process, chlorpromazine and prazosin deserve further investigation for use in conjunction with traditional chemotherapeutics.
    Journal
    |
    CASP3 (Caspase 3)
    |
    chlorpromazine
    2ms
    Psychopharmacological Treatment of Emotional Distress (clinicaltrials.gov)
    P4, N=80, Recruiting, Icahn School of Medicine at Mount Sinai | Initiation date: Feb 2024 --> May 2024
    Trial initiation date
    |
    olanzapine